HMGB1 and stroke disorder: The rapid early changes observed in experimental stroke models could be prevented by blocking β-adrenoceptors with propranolol or by neutralizing HMGB-1 activity with antibodies or an antagonist of its receptor, the receptor for advanced glycation end-products (RAGE) [51, 52].